None listed
Conditions
Interventions
Dietary Supplement : The test group or control group shall be randomly allocated and conducted in parallel tests, and the number of subject necessary for the human application test shall be 88 persons
Sponsors
PROSTEMICS
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Those who agree to participate in this examination and voluntarily signs a written consent form 2. Adult men and women aged 18 or older and 75 or younger 3. Those who have experienced abdominal pain at least once a week for at least three months within six months of visit 1, and falls under at least two of the following three cases: 1) Stomach pain symptoms are related to bowel movement 2) Symptoms occur related to changes in the number of bowel movement 3) Symptoms related to changes in forms of bowel movement
Exclusion criteria
Exclusion criteria: 1. Patients with uncontrolled hypertension(based on visit 1, systolic pressure of 180 mm Hg or higher, diastolic pressure of 110 mm Hg or higher, after stabilizing for 10 minutes) 2. Patients with uncontrolled diabetics(based on visit 1, fasting blood sugar 200 mg/dl or higher) 3. Those with history of chronic diseases diagnosed within 6 months of visit 1, such as malignancy, cerebrovascular disease (cerebral infarction, cerebral hemorrhage, etc.), heart disease (angina, myocardial infarction, heart failure, arrhythmia requiring treatment), etc. (but those with history of cerebrovascular and heart disease but who are clinically stable may participate in the test at the discretion of the investigator) 4. Those who have history of abdominal surgery excluding appendectomy and hernia surgery 5. Those who are taking Irritable Bowel Syndrome (IBS) treatment 6. Those diagnosed with inflammatory bowel disease or those with constipation-predominant irritable bowel symptoms 7. Those with lactose intolerance not controlled by food 8. Those who have any warning symptoms or warning signs of suspected organic disease * Warning symptoms: ? first symptoms occuring after age 50, ? symptoms with weight loss, ? severe diarrhea with hematochezia, ? fever, ? night symptoms, ? dysphagia * Warning signs: (1) Bloodstain shown in digital rectal exam, ? signs of anemia, ? abdominal mass, ? signs of intestinal obstruction, ? signs of malabsorption, ? signs of thyroid dysfunction 9. Those who have taken medications that affect gastrointestinal exercise(antispasmodics, prokinetics, antidiarrheals, laxatives) and dietary fiber supplements within two weeks of visit 1 10. Those who have consumed probiotic-health functional food within one week of visiting 1, or lactobacillus products such as fermented milk sustainedly(at least four times a week) 11. Those whose Creatinine is more than twice the normal upper limit of the testing institution 12. Those whose AST(GOT) or ALT(GPT) is more than four times the normal upper limit of the test institution 13. Those whose fecal calprotectin is more than four times the normal upper limit of the test institution 14. Those who are pregnant, breastfeeding, or have pregnancy plan during this human application test(women of fertile period can participate only if urine HCG test results are negative) 15. Those who have participated in another interventional clinical trial(including human application test) within three months of the commencement of this human application test, or plans to participate in another interventional clinical trial(including human application test) after the commencement of this human application test 16. Those who are judged inappropriate for this human application test by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity improvement rate of irritable bowel symptoms after 8 weeks of intake(fraction reduced by more than 50 points when IRS-SSS total score is applied) | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity improvement rate of irritable bowel symptoms after 4 weeks of intake;Individual items of severity improvement rate of irritable bowel symptoms after 4 and 8 weeks of intake;Number and form of bowel movements;Severity of irritable bowel symptoms and availability in the controllment of symptoms ;Overall improvement of irritable bowel symptoms;Quality of life assessment related to irritable bowel syndrome;Evaluation of satisfaction(overall satisfaction with the test and whether if the subjects want to continue in the future);Adverse reaction;Vital signs(blood pressure, pulse);Weight;Clinical laboratory test(Complete blood cell count/Admission Batt/Urinary test) | — |
Countries
Korea, Republic of
Contacts
Public ContactJOO SUNG KIM
Seoul National University Hospital
Outcome results
None listed